Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Z. Kadija, I. Campo, G. Rodi, F. Mariani, A. Corsico, P. Ernesto, M. Luisetti (Pavia, Italy). Baseline characteristics of the Italian cohort of patients affected by pulmonary alveolar proteinosis (PAP). Eur Respir J 2008; 32: Suppl. 52, 253

Member's Comments

No comment yet.

Related content which might interest you: Baseline characteristics of an Italian cohort of pulmonary alveolar proteinosis (PAP) patients Source: Annual Congress 2011 - Rare diffuse lung diseases Year: 2011 Pulmonary alveolar proteinosis, study of 29 cases Source: Annual Congress 2010 - Rare diffuse lung diseases Year: 2010 Clinical features of autoimmune pulmonary alveolar proteinosis from a large international patient cohort: baseline data from the IMPALA trial Source: International Congress 2019 – Rare and ultra-rare diseases and the lungs: updates and new perspectives Year: 2019 Baseline characteristics and survival of patients with idiopathic pulmonary fibrosis (IPF): analysis from the Swedish IPF registry Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Serum SP-A as predictor of disease progression in patients with pulmonary alveolar proteinosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Pulmonary alveolar proteinosis (PAP) - clinical features and response to treatment by bronchofiberoscopic lobar lavage Source: Eur Respir J 2005; 26: Suppl. 49, 541s Year: 2005 Clinical assessment and management of pulmonary alveolar proteinosis: the importance of a reference centre Source: Annual Congress 2009 - Pulmonary alveolar proteinosis: clearing the Milky Way Year: 2009 Analysis of baseline characteristics by emphysema extent in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Longitudinal observation of idiopathic pulmonary fibrosis (IPF) patients cohort from one center in Poland. Source: International Congress 2019 – Interstitial lung disease registries Year: 2019 Long term follow-up in patients with pulmonary alveolar proteinosis Source: Annual Congress 2011 - Rare diffuse lung diseases Year: 2011 Association of pulmonary alveolar proteinosis and fibrosis: patient with GATA2 deficiency Source: Eur Respir J 2016; 48: 1510-1514 Year: 2016 Determinants of protein concentration in whole lung lavage of patients with pulmonary alveolar proteinosis Source: Annual Congress 2009 - From genetics to clinics in diffuse parenchymal lung diseases Year: 2009 Peculiarities of pulmonary alveolar proteinosis (PAP) due to exogenous factors Source: Virtual Congress 2020 – Occupational exposure as a cause of respiratory disease Year: 2020 Whole lung lavage therapy (WLL) of pulmonary alveolar proteinosis (PAP): A global survey of current practices and procedures Source: International Congress 2016 – Orphan diseases I Year: 2016 Whole lung lavage (WLL) in pulmonary alveolar proteinosis (PAP): long-term lung function follow-up Source: Eur Respir J 2001; 18: Suppl. 33, 220s Year: 2001 Pulmonary alveolar proteinosis (PAP) in exogenous toxic alveolitis (ETA) patients Source: International Congress 2015 – Occupational disease: clinical cases and series Year: 2015 A gene network to predict the clinical response to whole lung lavage (WLL), in pulmonary alveolar proteinosis (PAP). Source: International Congress 2017 – Novel and old entities Year: 2017 Our cases with pulmonary alveolar proteinosis Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018 Clinical features of secondary pulmonary alveolar proteinosis: pre-mortem cases in Japan Source: Eur Respir J 2011; 37: 465 Year: 2011